Engineered Multispecific antibodies – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals

Engineered Multispecific Antibodies Report Overview

Multi-specific antibodies that are engineered to recognize two or more epitopes located on the same or distinct targets are a high-impact innovation and will continue to remain so in the near-term. Engineered multi-specific antibodies is an accelerating innovation among 80+ key innovation areas in the pharma industry according to the innovation s-curve framework.

Innovation S-Curve – Innovation Areas

Buy the Full Report for More Engineered Multispecific Antibodies Innovation Insights, Download a Free Report Sample

Engineered multispecific antibodies market research report provides insights into engineered multispecific antibodies’ tech activities, including informed R&D, strategic planning, competitive edge, market potential, and technology initiatives.

Engineered Multispecific Antibodies Technology Foresights

Chimeric multi-specific antibodies, particularly bispecific antibodies (bsAbs), are rapidly gaining traction in the pharmaceutical industry. The approval rate of bsAbs surged dramatically from 2021 to 2023, with eleven new therapies added to the market, indicating a robust growth trajectory in this sector. The increasing demand for efficient cancer treatments and the limitations of traditional monoclonal antibodies (mAbs) have paved the way for these innovative therapeutics.

Buy the Full Report for More Engineered Multispecific Antibodies Technology Foresights, Download a Free Report Sample

Engineered Multispecific Antibodies Segmentation by Drug Types

IN 2024, innovator drugs predominantly represented engineered multispecific antibodies whereas innovator (NME) and biosimilar accounted for minimal shares. Furthermore, Amgen Inc, Xencor Inc, Johnson & Johnson among others are the major key players in the innovator drugs type.

Engineered Multispecific Antibodies Drug Type Analysis, 2024 (%)

Buy the Full Report for More Engineered Multispecific Antibodies Drug Type Insights, Download a Free Report Sample

Engineered Multispecific Antibodies Segmentation by Route of Administration

The key routes of administration of engineered multispecific antibodies are intravenous, subcutaneous, oral, topical, and inhalational among others. Intravenous is the prominent RoA followed for engineered multispecific antibodies.

Engineered Multispecific Antibodies RoA Analysis, 2024 (%)

Buy the Full Report for More Engineered Multispecific Antibodies RoA Insights, Download a Free Report Sample

Engineered Multispecific Antibodies Drugs – Competitive Landscape

The key sponsors in engineered multispecific antibodies drugs are F. Hoffmann-La Roche Ltd, Akeso Inc., Amgen Inc, Johnson & Johnson, and Xencor Inc among others. F. Hoffmann-La Roche Ltd was the leading sponsor of engineered multispecific antibodies drugs.

Engineered Multispecific Antibodies Drug Sponsors, 2024 (%)

Buy the Full Report for More Engineered Multispecific Antibodies Drug Sponsor Insights, Download a Free Report Sample

Segments Covered in the Report

Engineered Multispecific Antibodies Drug Type Outlook (2024)

• Innovator
• Innovator (NME)
• Biosimilar

Engineered Multispecific Antibodies Drugs RoA Outlook (2024)

• Intravenous
• Subcutaneous
• Parenteral
• Intravenous Drip
• Intravitreal
• Inhalational
• Topical
• Oral
• Intratumor
• Intravenous Bolus

Scope

The report provides:

• Innovation Insights: innovation examples by each use case segment of various sectors to present key trends.
• Key player: This represents a sample list of key players in each use case highlighted in the report.
• Startups: This represents a sample list of emerging startups in each use case highlighted in the report.
• University: This represents a sample list of leading universities in each use case highlighted in the report.

Key Highlights

• Multi-specific antibodies are a high-impact innovation in the pharmaceutical industry and are expected to continue to be so in the near-term. Patent trends show a noticeable surge in 2023, indicating increasing interest and investment in this area.
• Small biotech and startups have become the major force driving patent filings in the multi-specific antibodies space since 2022. China has also emerged as a dominant geography in this field, with a rise in activity since 2020.
• Oncology, infectious diseases, and hematological diseases are the most mentioned indications in patents related to multi-specific antibodies.
• Regeneron, Roche, and Amgen are the top patent filers among big pharma companies in the multi-specific antibodies space. CSL is a recent entrant, while Innovent, Zymeworks, and AstraZeneca rank high on the generality index.
• Systimmune, Biotheus, and Numab are among the startups and small biotech companies identified in the multi-specific antibodies space. Many of these startups have secured multi-year development contracts with big pharma companies.

Reasons to Buy

• No surprise that technology has been a driving force in business transformation for years, but the term ‘emerging technologies’ has all of the sudden become the key catalyst to drive the next wave of innovation across sectors.
• Engineered multispecific antibodies or engineered multispecific antibodies provides comprehensive insights into the latest research, patents, clinical trials, and market trends. These reports aid strategic decision-making by offering data on top pharma companies, startups, and universities. They facilitate competitive analysis, helping identify opportunities and threats. Additionally, they guide innovation and uncover market opportunities, and assist in navigating regulatory and compliance challenges. Overall, these reports are valuable tools for staying informed and making well-informed decisions in the biotech and pharmaceutical industries.